"Florida Digestive Health Specialists strives to exceed your expectations as a trusted and valued provider for all digestive health services. It is our goal to provide unprecedented, compassionate care for comprehensive gastroenterology issues including Crohn's, acid reflux, colitis, hemorrhoids, constipation, IBS and more. Additionally, our gastroenterologists use cutting-edge equipment and innovative, research-based treatments to enhance digestive care options. We are committed to continually improving care through compassion, patient education and an in-depth understanding of your individual health needs."

During the past decade, Florida Center for Gastroenterology conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 16 clinical trials were completed, i.e. on average, 72.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 10 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Florida Center for Gastroenterology" #1 sponsor was "Celgene" with 8 trials, followed by "Pfizer" with 3 trials sponsored, "Takeda" with 3 trials sponsored, "Arena Pharmaceuticals" with 2 trials sponsored and "Galapagos NV" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Florida Center for Gastroenterology" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 3 trials as a collaborator, "Gilead Sciences" with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "SCRI Development Innovations, LLC" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Florida Center for Gastroenterology" are "Crohn's Disease" (8 trials), "Crohn Disease" (6 trials), "Ulcerative Colitis" (6 trials), "Chronic Hepatitis C" (3 trials) and "Colitis, Ulcerative" (3 trials). Many other conditions were trialed in "Florida Center for Gastroenterology" in a lesser frequency.

Most popular intervention types in "Florida Center for Gastroenterology" are "Drug" (24 trials), "Other" (4 trials), "Biological" (3 trials), "Combination Product" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Etrasimod" (5 trials), "Ozanimod" (3 trials), "RPC1063" (3 trials) and "Filgotinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Florida Center for Gastroenterology" are 27 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Florida Center for Gastroenterology". undefined are not yet recruiting, 6 are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 16 completed trials in Florida Center for Gastroenterology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Florida Center for Gastroenterology, 0 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".